Products for assisted reproduction

Vitrolife

Vitrolife is a Swedish medtech company focused on developing, manufacturing and marketing products used in In Vitro Fertilsation (IVF). Vitrolife offers its customers a wide range of products and solutions, including culture media, disposable products and capital equipment products. Vitrolife is a global company, with sales in some 110 countries.

Financials

Vitrolife

SEKm 2017 2018 2019
Sales 1046 1133 1337
Sales growth (%) 22,2 8,3 18
EBITDA 407 461 523
EBITDA margin (%) 38,9 40,7 39,1
EBIT adj 341 393 440
EBIT adj margin (%) 32,6 34,7 32,9
Pretax profit 341 393 442
EPS rep 2,44 2,82 3,16
EPS growth (%) 38,4 15,6 12,1
EPS adj 2,73 3,11 3,45
DPS 0,74 1 1
EV/EBITDA (x) 32,2 35,9 31,2
EV/EBIT adj (x) 38,5 42,1 37
P/E (x) 51,1 55,6 49,6
P/E adj (x) 45,7 50,4 45,4
EV/sales (x) 12,5 14,6 12,2
FCF yield (%) 2,2 1 2,2
Dividend yield (%) 0,6 0,6 0,6
Net IB debt/EBITDA -1 -0,9 -1,3

Main shareholders

Vitrolife

Main shareholders Share capital % Voting shares %
William Demant Invest A/S 22.4 % 22.4 %
Bure Equity 20.8 % 20.8 %
Capital Group 4.6 % 4.6 %
Lannebo Fonder 3.3 % 3.3 %
Eccenovo AB 2.1 % 2.1 %
Morgan Stanley Investment Management 1.9 % 1.9 %
Norges Bank 1.9 % 1.9 %
Vanguard 1.5 % 1.5 %
La Financière de l'Echiquier 1.1 % 1.1 %
GLG Partners 1.1 % 1.1 %